Faculty Appointments
Patient Care Settings
Cancer, Hospital Medicine
Biography
I am a clinician and researcher specializing in the care of patients with both Non Hodgkin and Hodgkin lymphomas. Areas of particular interest include aggressive B-cell lymphomas, autologous stem cell transplantation and cellular therapy including chimeric antigen receptor (CAR) T-cells.
Lymphomas are a complex group of diseases and require a multidisciplinary team to manage. We are fortunate to have an excellent team at the Wilmot Cancer Institute including hematology and oncology, radiation oncology, hematopathology, dermatology, neurology, nursing, advanced practice providers, social work and members of the clinical trials office.
I am actively engaged in clinical trials research and feel that this is an important component of care for lymphoma patients.
Professional Background
Dr. Reagan is an Associate Professor of Medicine at the Wilmot Cancer Institute.
Dr. Reagan received his medical degree from Upstate Medical University in Syracuse, NY. He completed his internship and residency at the University of Virginia. He then served as a chief resident at the University of Virginia. He completed his fellowship in hematology at the Wilmot Cancer Institute at the University of Rochester Medical Center.
He started his faculty appointment at the Wilmot Cancer Institute in July 2015.
Credentials
Education
2009
MD | SUNY Upstate College of Health Professions
Post-doctoral Training & Residency
07/01/2013 - 06/30/2015
Fellowship in Hematology & Oncology at University of Rochester Medical Center
07/01/2012 - 07/01/2013
Residency in Internal Medicine at University of Virginia-Radiology GME
07/01/2010 - 07/01/2012
Residency in Internal Medicine at University of Virginia-Radiology GME
07/01/2009 - 07/01/2010
Internship in Internal Medicine at University of Virginia-Radiology GME
VIEW ALL expand_more
Awards
2022
Wilmot Cancer Institute Inspiration Award Immune Effector Cell Therapy Team
2018
Lymphoma Research Foundation Clinical Research Mentoring Program
2015
American Society of Hematology Clinical Research Training Institute
2014
John and Carol Bennett Travel Fellowship Award
Sponsor: John and Carol Bennett
Location: Wilmot Cancer Institute
2009
Alpha Omega Alpha, Upstate Medical University
Sponsor: Upstate Medical University
2005
Phi Beta Kappa, St. Lawrence University
Sponsor: St. Lawrence University
2004
Academic All American, Football, St. Lawrence University
Sponsor: St. Lawrence University
Beta Beta Beta, Biological Honor Society, St. Lawrence University
Sponsor: St. Lawrence University
VIEW ALL expand_more
Clinical Trials
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Lead Researcher: Patrick M Reagan
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a drug called vedotin. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, and delivers vedotin to kill them. Chemotherapy drugs, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving mosunetuzumab and/or polatuzumab vedotin after chemotherapy and CAR T-cell therapy may be more effective at controlling or shrinking the cancer than not giving them.
View Study Details
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
Lead Researcher: Patrick M Reagan
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
View Study Details
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Lead Researcher: Patrick M Reagan
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.
View Study Details
A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Lead Researcher: Patrick M Reagan
Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL
View Study Details
Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
Lead Researcher: Patrick M Reagan
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
View Study Details
Publications
Journal Articles
6/26/2023
Roschewski M, Patel MR, Reagan PM, Saba NS, Collins GP, Arkenau HT, de Vos S, Nuttall B, Acar M, Burke K, White RD, Udriste M, Sharma S, Dougherty B, Stetson D, Jenkins D, Mortlock A, Forcina A, Munugalavadla V, Flinn I. "Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2023 Jun 26; Epub 2023 Jun 26.
6/21/2023
Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM. "Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma." Leukemia & lymphoma.. 2023 Jun 21; :1-4. Epub 2023 Jun 21.
6/5/2023
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL, . "Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma." The New England journal of medicine.. 2023 Jun 5; Epub 2023 Jun 05.
VIEW ALL PUBLICATIONS